ARCHIVES

Large Phase III Trial Seeks Optimal Use Of Tykerb vs. Herceptin In Breast Cancer

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

$293 Million NCI Budget Cut To Drop Grant Success Rate

May 10, 2013

Four CIDAC Contracts Will Go To Cancer Research Centers; RFPs To Be Released January or February

December 20, 1974

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014

IOM To Form Committee To Investigate Duke Genomics Research

October 1, 2010

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006

ACS To Accept Database On Method Of Unconventional Rx

November 26, 1993